123 related articles for article (PubMed ID: 17513601)
1. Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor alpha.
Zwart W; Griekspoor A; Rondaij M; Verwoerd D; Neefjes J; Michalides R
Mol Cancer Ther; 2007 May; 6(5):1526-33. PubMed ID: 17513601
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer.
Michalides R; Griekspoor A; Balkenende A; Verwoerd D; Janssen L; Jalink K; Floore A; Velds A; van't Veer L; Neefjes J
Cancer Cell; 2004 Jun; 5(6):597-605. PubMed ID: 15193262
[TBL] [Abstract][Full Text] [Related]
3. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; Medema RH; Hartman J; Lykkesfeldt AE; Lam EW
Oncogene; 2010 May; 29(20):2983-95. PubMed ID: 20208560
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs.
Nichols M; Cheng P; Liu Y; Kanterewicz B; Hershberger PA; McCarty KS
Breast Cancer Res Treat; 2010 Apr; 120(3):761-8. PubMed ID: 19526339
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion.
JavanMoghadam S; Weihua Z; Hunt KK; Keyomarsi K
Cell Cycle; 2016 Jun; 15(12):1579-90. PubMed ID: 27049344
[TBL] [Abstract][Full Text] [Related]
6. Isoform-selective interactions between estrogen receptors and steroid receptor coactivators promoted by estradiol and ErbB-2 signaling in living cells.
Bai Y; Giguére V
Mol Endocrinol; 2003 Apr; 17(4):589-99. PubMed ID: 12554772
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells.
Badia E; Docquier A; Busson M; Lapierre M; Pujol P; Balaguer P; Cavailles V
J Steroid Biochem Mol Biol; 2012 Oct; 132(1-2):176-85. PubMed ID: 22652558
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release.
Kansra S; Yamagata S; Sneade L; Foster L; Ben-Jonathan N
Mol Cell Endocrinol; 2005 Jul; 239(1-2):27-36. PubMed ID: 15950373
[TBL] [Abstract][Full Text] [Related]
9. Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens.
Leblanc K; Sexton E; Parent S; Bélanger G; Déry MC; Boucher V; Asselin E
Int J Oncol; 2007 Feb; 30(2):477-87. PubMed ID: 17203231
[TBL] [Abstract][Full Text] [Related]
10. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
Kim K; Thu N; Saville B; Safe S
Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera.
Chen D; Washbrook E; Sarwar N; Bates GJ; Pace PE; Thirunuvakkarasu V; Taylor J; Epstein RJ; Fuller-Pace FV; Egly JM; Coombes RC; Ali S
Oncogene; 2002 Jul; 21(32):4921-31. PubMed ID: 12118371
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen regulation of bone growth and endocrine function in the ovariectomized rat: discrimination of responses involving estrogen receptor α/estrogen receptor β, G protein-coupled estrogen receptor, or estrogen-related receptor γ using fulvestrant (ICI 182780).
Fitts JM; Klein RM; Powers CA
J Pharmacol Exp Ther; 2011 Jul; 338(1):246-54. PubMed ID: 21464335
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-alpha hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome.
Berry NB; Fan M; Nephew KP
Mol Endocrinol; 2008 Jul; 22(7):1535-51. PubMed ID: 18388150
[TBL] [Abstract][Full Text] [Related]
14. The genomic regulatory elements for estrogen receptor alpha transactivation-function-1 regulated genes.
Arao Y; Hamilton KJ; Grimm SA; Korach KS
FASEB J; 2020 Dec; 34(12):16003-16021. PubMed ID: 33064339
[TBL] [Abstract][Full Text] [Related]
15. Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis.
Chen Y; Li Z; He Y; Shang D; Pan J; Wang H; Chen H; Zhu Z; Wan L; Wang X
Toxicol Appl Pharmacol; 2014 Mar; 275(2):176-81. PubMed ID: 24440569
[TBL] [Abstract][Full Text] [Related]
16. Decreased responsiveness of naturally occurring mutants of human estrogen receptor alpha to estrogens and antiestrogens.
Komagata S; Nakajima M; Tsuchiya Y; Katoh M; Kizu R; Kyo S; Yokoi T
J Steroid Biochem Mol Biol; 2006 Jul; 100(1-3):79-86. PubMed ID: 16713253
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha.
Long X; Nephew KP
J Biol Chem; 2006 Apr; 281(14):9607-15. PubMed ID: 16459337
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor (ER)-mediated transcriptional regulation of the human corticotropin-releasing hormone-binding protein promoter: differential effects of ERalpha and ERbeta.
van de Stolpe A; Slycke AJ; Reinders MO; Zomer AW; Goodenough S; Behl C; Seasholtz AF; van der Saag PT
Mol Endocrinol; 2004 Dec; 18(12):2908-23. PubMed ID: 15345745
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
